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Deficiencies in the activity of cytochrome c oxidase (COX), the terminal enzyme in the respiratory chain, are a
frequent cause of autosomal recessive mitochondrial disease in infants. These patients are clinically and genetically
heterogeneous, and all defects so far identified in this group have been found in genes coding for accessory proteins
that play important roles in the assembly of the COX holoenzyme complex. Many patients, however, remain
without a molecular diagnosis. We have used a panel of retroviral vectors expressing human COX assembly factors
in these patients to identify the molecular basis for the COX deficiency by functional complementation. Here we
show that overexpression of COX15, a protein involved in the synthesis of heme A, the heme prosthetic group for
COX, can functionally complement the isolated COX deficiency in fibroblasts from a patient with fatal, infantile
hypertrophic cardiomyopathy. Mutation analysis of COX15 in the patient identified a missense mutation (C700T)
on one allele, changing a conserved arginine to tryptophan (R217W), and a splice-site mutation in intron 3 on the
other allele (C447-3G), resulting in a deletion of exon 4. This splicing error introduces a frameshift and a premature
stop codon, resulting in an unstable mRNA and, likely, a null allele. Mitochondrial heme A content was reduced
in the patient’s heart and fibroblast mitochondria, and levels of heme O were increased in the patient’s heart. COX
activity and the total amount of fully assembled enzymewere reduced by 50%–70% in patient fibroblasts. Expression
of COX15 increased heme A content and rescued COX activity. These results suggest that reduced availability of
heme A stalls the assembly of COX. This study establishes COX15 as an additional cause, along with SCO2, of
fatal infantile, hypertrophic cardiomyopathy associated with isolated COX deficiency.
Introduction
Cytochrome c oxidase (COX) deficiency is one of the
most frequent causes of respiratory-chain defects in
humans. Patients with COX deficiencies can present
with a number of different clinical phenotypes, in-
cluding Leigh syndrome, a French Canadian form of
Leigh syndrome, hypertrophic cardiomyopathy and
myopathy, fatal infantile COX deficiency, and revers-
ible COX deficiency in skeletal muscle (Robinson
2000, Shoubridge 2001a, 2001b; Barrientos et al.
2002).
COX is the terminal enzyme of the respiratory chain
and catalyzes the reduction of molecular oxygen. In
mammals, it is composed of 13 subunits, 10 of which
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are encoded by nuclear genes. The three mtDNA en-
coded subunits form the catalytic core of the enzyme,
but the exact function of the nuclear-encoded structural
genes is largely unknown. The complex is embedded in
the inner mitochondrial membrane and functions as a
dimer. The enzyme contains two copper-binding sites
(CuA and CuB), two hemes (a and a3), and a magnesium
and a zinc ion. The biogenesis of the COX complex
requires a large number of accessory or assembly pro-
teins that are not themselves part of the complex but
are necessary for various stages of the process, including
transcription, translation and processing, and mem-
brane insertion of the structural subunits, as well as
synthesis, chaperoning, and addition of the prosthetic
groups (Barrientos et al. 2002). Although the total num-
ber of proteins necessary for the biogenesis of the intact
complex is not precisely known, 130 different genetic
complementation groups for COX assembly have been
identified in the yeast Saccharomyces cerevisiae (Mc-
Ewen et al. 1986; Tzagoloff and Dieckmann 1990), of
which 120 have been assigned to accessory proteins
(Barrientos et al. 2002). More than half of these have
known human homologues.
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Table 1
COX15 Primers
REGION
SEQUENCE
PRODUCT SIZE
(bp)
Upstream
(5′r3′)
Downstream
(5′r3′)
cDNA 1124bp (EX1rEX9)a tgaaggggaggcagtatctg cagtgagcaaagccaaggag 1,153
cDNA 457bp (EX3rEX5) cctctcgatggtagattggcattt cggagggagtagcagtgacagtg 457
Exon 1 gcctgcagtttccacttg gggctctgatctgaacctat 505
Exon 2 aaggctgatgcagtaatccagata tcctcagtcaacctgtgcttctac 402
Exon 3/4 atggcagctgtttctgacaa aacaatgccaactaggaagctc 837
Exon 5 caagatcccgccactg gtccccatttaacgaacaat 598
Exon 6 atggggtagaagggaaaaca tgaagatgggggaatgaga 429
Exon 7 ttggggtgggagcaggta gtagggggacaggggtgaat 564
Exon 8 gaagaggatggtggaaga ttttgtagagatggggtttt 474
Exon 9 variant 1b ggggaattttaggtttatca tggcagacatttctttctc 587
Exon 9 variant 2c gcccagctagttcctcttt aggggttctggactcatcat 704
Intron 3/Exon4 cttctaagcccccaaatccaaagtc ttctgtcagtgtcatatcatgattcaaCctd 192
a Downstream primer is specific to exon 9 of the cox15 variant 1 mRNA transcript. This cDNA does not
amplify 80 bp of 5′ and 64 bp of 3′ cDNA-coding sequence.
b These primers are specific to COX15.1.
c These primers are specific to COX15.2.
d This primer has a mismatch at the underlined C (reference ).sequencep g
Mutations in the three mtDNA-encoded COX sub-
units have been reported in several patients in associ-
ation with a number of different, mostly encephalomyo-
pathic, clinical phenotypes (Shoubridge 2001a); however,
mutations have not yet been found in any of the 10
nuclear-encoded COX structural subunits (Jaksch et al.
1998). In contrast, gene defects have been reported in
four different factors important for the biogenesis of the
COX complex, and unexpectedly, all are primarily as-
sociated with different clinical phenotypes: SURF1
(Leigh syndrome) (Tiranti et al. 1998; Zhu et al. 1998),
SCO2 (hypertrophic cardiomyopathy) (Papadopoulou
et al. 1999; Jaksch et al. 2000), SCO1 (ketoacidotic
coma and hepatopathy) (Valnot et al. 2000a), and
COX10 (tubulopathy and leukodystrophy) (Valnot et
al. 2000b).
COX15, one of the COX assembly factors identified
in yeast, plays a key role in the mitochondrial heme
biosynthetic pathway in which protoheme (heme B) is
converted to heme A, the prosthetic heme group in
COX. Two splice variants of the gene (COX15.1 and
COX15.2 [GenBank accession numbers NM_078470
and NM_004376]) that differ in the predicted C-ter-
minal amino acid sequence and 3′ UTR have been de-
scribed in humans, but the functional significance of the
different isoforms is unknown (Petruzzella et al. 1998).
The gene is essential for the biogenesis of COX in yeast
(Glerum et al. 1997), the model organism in which the
details of the pathway have been most intensively in-
vestigated. Heme A biosynthesis begins with farnesy-
lation of the vinyl group at carbon C-2 of heme B,
forming heme O, a reaction catalyzed by a heme A:
farnesyltransferase encoded by COX10. The heme O
methyl group on carbon C-8 is oxidized to a carboxy-
methyl group—a reaction hypothesized to be carried out
by a three-component heme mono-oxygenase, consist-
ing of Cox15p, ferredoxin, and ferredoxin reductase
(Barros et al. 2001, 2002; Barros and Tzagoloff 2002)—
and to a formyl group by an as-yet-uncharacterized en-
zyme. COX15 deletion mutants are blocked in heme A
but not in heme O biosynthesis (Barros et al. 2001).
Here, we report pathogenic mutations in COX15 in
a patient with isolated COX deficiency and an early
onset, fatal hypertrophic cardiomyopathy. The molec-
ular defect was identified by functional complementa-
tion in patient fibroblasts using a retroviral expression
system. We show that overexpression of COX15 in-
creases the synthesis of heme A, which, in turn, influ-
ences the assembly of the COX complex and rescues
COX activity.
Material and Methods
Cell Lines
Primary cell lines were established from patient skin
fibroblasts. The patient and control cell lines were trans-
duced with a retroviral vector expressing the E6E7 genes
of type-16 human papilloma virus and a retroviral vector
expressing the protein component of human telomerase
to immortalize the cells (Yao and Shoubridge 1999). The
fibroblasts were grown at 37C in an atmosphere of 5%
CO2 in high glucose Dulbecco’s modified Eagle medium
supplemented with 10% fetal bovine serum.
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Cardiac Tissue and Preparation of Mitochondria
Postmortem cardiac-tissue specimens from the pa-
tients and control individuals were removed and frozen
!30 min after death. Heart and fibroblast homogenates
(5%) prepared in 250 mM sucrose/10 mM Tris-HCl/1
mM EDTA (pH 7.4) were centrifuged twice for 10 min
at 600 g to obtain postnuclear supernatant. Mitochon-
dria were pelleted by centrifugation for 20min at 10,000
g.
COX Assembly cDNA Constructs
Ten retroviral vectors were created with the Gateway
Cloning system (Invitrogen). cDNAs from each of the
human COX assembly genes SURF1, SCO1, SCO2,
COX17, COX11, COX15.1 (variant 1), COX18,
COX10, OXA1, and PET191were amplified byOneStep
RT-PCR (Qiagen) using specific primers modified for
cloning into Gateway vectors. The PCR constructs were
cloned into a Gateway-modified retroviral expression
vector, pLXSH (Miller and Buttimore 1986). The fidelity
of cDNA clones was confirmed by automated DNA
sequencing.
Virus Production and Infection
Stable virus-producing cell lines were generated using
procedures described elsewhere (Miller et al. 1993). In
brief, the retroviral constructs were used to transfect a
GP  E86 ecotropic packaging cell line (Markowitz et
al. 1988), and the virus produced was used to infect the
amphotropic packaging cell line PA317 (Miller and But-
timore 1986). Fibroblasts were infected by exposure to
virus-containing medium in the presence of 4 mg/ml of
polybrene, as described by Lochmuller et al. (1999).
Electrophoretic Methods
Blue-Native PAGE (BN-PAGE) (Schagger 1995) was
used for separation of samples in the first dimension on
6%–15% polyacrylamide gradient gels, as described
elsewhere (Klement et al. 1995). Mitoplasts were pre-
pared from mitochondria by treatment with 0.8 mg of
digitonin/mg of protein, as described elsewhere (Klement
et al. 1995). Mitoplasts or mitochondria were solubi-
lized with 1% lauryl maltoside, and 10–20 mg of the
solubilized proteins were used for electrophoresis. In-gel
qualitative assays for complex I and COX activity were
performed as described by Zerbetto et al. (1997). COX
and complexes I–III were detected by immunoblot anal-
ysis using monoclonal antibodies (Molecular Probes).
Enzyme Activity
COX and citrate synthase activities were measured in
fibroblast cell extracts, as described elsewhere (Srere
1969; Capaldi et al. 1995). Protein concentration was
measured by the Bradford method (Bradford 1976).
Extraction and Separation of Mitochondrial Hemes and
HPLC
Mitochondrial hemes were prepared and analyzed by
high pressure liquid chromatography (HPLC), as de-
scribed elsewhere (Barros et al. 2001). Briefly, total heme
was extracted from 100 (heart) to 600 (fibroblast) mg of
mitochondrial protein, with 0.5ml of acetone containing
2.5% HCl. The mixture was vortexed, centrifuged for
5 min at 15,000 g, and mixed with 600 ml of 50%
acetonitrile. Insoluble material was removed by a second
centrifugation. The extract was adjusted to ∼pH 3.5
with 1.65 M ammonium hydroxide, was clarified by
centrifugation, and was applied to a 15# 0.46 cm CSC-
Kromacil 5 micron C18 column (Chromatography Sci-
ences). Hemes were eluted at a flow rate of 1 ml/min
using a 30%–50% acetonitrile gradient over the first 5
ml, followed by a 50%–75% linear acetonitrile gradient
over the subsequent 35 ml. All gradient solutions con-
tained 0.05% trifluoroacetic acid. The elution of heme
compounds was monitored at 400 nm. The identity of
the heme A and heme B peaks was confirmed by ESI
tandem mass spectrometry.
PCR/Gene Sequencing
Primer pairs shown in table 1 were used for the PCR
amplification and sequencing of the COX15 exons and
for the RT-PCR amplification of fibroblast COX15
mRNA (see table 1). RT-PCR was performed on total
RNA from fibroblasts with the OneStep RT-PCR kit
(Qiagen). PCR amplifications were performed with the
Expand High Fidelity PCR system (Roche Diagnostics)
as follows: 1#Expand bufferwithMgCl2, 125 mMdNTP,
2.5 mM primers, and 0.75 mM Expand enzyme mix.
Reaction conditions were as follows: 94C for 4 min,
35 cycles with denaturing phase of 94C for 20 s, an-
nealing phase of 55C for 30 s, and extension phase of
72C for 45 s, with a final extension phase of 72C for
7 min.
The presence of the C700T mutation was verified by
StyI digestion of an exon 5 PCR product. To confirm
the intron 3 splice-acceptor site transversion mutation
(C447-3G), a mismatch primer was used to amplify an
intron 3/exon 4 region (table 1), and the PCR product
was digested with ScrfI.
Results
Clinical Presentation
The clinical history of patient N has been described
elsewhere (Kennaway et al. 1990). In brief, patient Nwas
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Table 2
Cytochrome C Oxidase Activity in Patient Heart
and Fibroblasts
Sample COX/CS Activitya % Control
Heart:
Control 5.6  3.2 (n p 6) 100
Patient N 0.4 7
Fibroblasts:
Control .82  .21 (n p 16) 100
Control .89  .18 (n p 5) 100
Patient N .24  .11 (n p 6) 28
Patient N  COX15 .51  .14 (n p 5) 61
a COX and citrate synthase (CS) were measured as described
in the “Material and Methods” section. The number in paren-
theses indicates the number of independent measurements.
Figure 1 Abnormal ultrastructure of cardiac muscle in the patient. Electron micrograph of left ventricular cardiac tissue in the patient
demonstrating replacement of myofibils with large numbers of morphologically abnormal mitochondria (#14,000).
the sixth child of a healthy 29-year-old woman and the
first child of a nonconsanguinous white couple; all half-
siblings were normal. Shortly after birth, patient N pre-
sented with midfacial hypoplasia, lactic acidosis, seizures,
and hypotonia. Echocardiogram on day 6 showed no ven-
tricular enlargement, but she died at age 24 d from a
massive biventricular hypertrophic cardiomyopathy.
Pathologic examination of liver and muscle tissue (day
23) was normal. Autopsy findings included cardiac ab-
normalities, pneumonia, eosiniphilic infiltrates in mul-
tiple tissues, and abnormally small height, weight, head
circumference, and internal organs (brain, lung, and kid-
ney). Electron microscopy of skeletal muscle tissue was
normal. Electron microscopy of the heart showed severe
loss of myofibrillar material and greatly increased num-
bers of mitochondria with abnormal shapes, abnormally
arranged cristae, and numerous matrix densities (fig. 1)
compared with normal heart as shown byMatthews and
Martin (1971, p. 119). COX activity was severely de-
creased in heart (7% of control; table 2) and in kidney
and liver (!25% of control) and was in a low–normal
range in muscle. Other respiratory chain activities were
normal. Cytochrome spectra showed barely detectable
levels of cytochrome aa3 in heart mitochondria, whereas
it was 37% of normal in muscle mitochondria. Immu-
noblot analysis showed markedly low COX subunits II,
III, VIa, VIb, VIc, and VIIa in the patient’s heart mi-
tochondria, whereas subunits IV and Va were less af-
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Figure 2 Blue-Native PAGE analysis of COX levels in patient heart mitochondria. Heart mitochondria (10 mg protein) from two control
subjects (C1 and C2) and the patient (N) were separated by BN-PAGE, and the content of COX, Complex I (Co I), Complex II (Co II), and
Complex III (Co III) were determined by immunoblot analysis using antibodies against COX subunits I and IV (COX I and COX IV), the 39-
kDa subunit of complex I, the 70-kDa subunit of complex II, and the Core1 protein of complex III. Patient heart mitochondria show a specific
reduction in the total amount of fully assembled COX but no evidence of any subcomplexes. The arrow indicates the small amount of unassembled
COX IV in the patient. The migration of molecular mass standards is indicated on the left.
fected (Kennaway et al. 1990). Analysis of mtDNA
showed no mtDNA deletions and no pathogenic tRNA
or COX I–III mutations.
Assembly of COX
Blue-Native PAGE of patient heart tissue showed a
decreased amount of fully assembled COX (fig. 2), in
agreement with the low COX activity. The subcomplex,
previously described in patients with SURF1 (Coenen et
al. 1999; Tiranti et al. 1999), was not detected using
either anti-COX IV or anti-COX I antibodies. Nonas-
sembled subunit IV was present in heart tissue from the
patient, consistent with the milder reduction of COX IV
on immunoblot analysis. Other respiratory chain com-
plexes were present at the same level as in control in-
dividuals. A similar pattern was found in patient fibro-
blasts, although the COX activity (28% of control; table
2) and COX protein levels (fig. 3A) were less affected
than in heart tissue. In-gel assays showed no detectable
COX activity in patient fibroblasts (fig. 3B) or heart
(data not shown), whereas complex I activity was
normal.
Overexpression of COX Assembly Factors
To determine whether mutations in any of the known
human COX assembly factors were responsible for
the low COX activity in patient N, the cDNAs coding for
10 different factors (SURF1, SCO2, SCO1, COX10,
COX11, COX15, COX17, COX18, OXA1, and
PET191) were individually overexpressed in patient fi-
broblasts using a retroviral expression system. Overex-
pression of COX15 restored COX activity to ∼60% of
the control levels when normalized to citrate synthase
(table 2). COX activity was not restored by any other
COX assembly factor (data not shown). Overexpression
of COX15 in control cells or in other COX-deficient
patient fibroblast lines (Leigh syndrome SURF1 and
non-SURF1 patients) did not significantly affect COX
activity.
To establish whether overexpression of COX15 in pa-
tient fibroblasts rescued the assembly of COX, BN-
PAGE analysis was performed. Immunoblot analysis
showed near-normal levels of fully assembled COX
when compared with control fibroblasts, and ∼60%
when compared with control fibroblasts overexpressing
COX15 (fig. 3A), indicating that COX15 plays a role
in the biosynthesis of a fully assembled COX. No sub-
Figure 3 Rescue of COX content and activity in patient fibroblasts. Mitoplasts (20 mg protein) isolated from patient (N) and control (C)
fibroblasts and patient and control fibroblasts overexpressing COX15 (NCOX15 and CCOX15, respectively) were analyzed by BN-PAGE.
A, Western blot analysis using antibodies against COX subunits I and IV and against the 70-kDa subunit of Complex II (Co II) and the Core1
protein of Complex III (Co III). Overexpression of COX15 rescues COX levels in patient mitochondria. B, In-gel activity staining of COX and
Complex I demonstrating restoration of COX activity in patient fibroblasts overexpressing COX15. The migration of molecular mass standards
is indicated on the left.
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Figure 4 Sequence analysis of COX15. DNA sequence analysis of COX15 cDNA (A) and genomic DNA (C) from patient fibroblasts
identifies the two pathogenic mutations: a C700T transition mutation in exon 5 and a C447-3G mutation in the splice acceptor of intron 3.
The mutations shown are on the sense strand. The C700T mutation was confirmed by RFLP analysis with StyI (B). When the mutation is
present, the enzyme digests a 598-bp PCR product once, producing two fragments of 402 and 196 bp. The wild-type PCR product remains
uncut. A PCR utilizing a mismatch reverse primer to create a ScrfI site in wild-type DNA was used to confirm the C447-3G mutation (D).
ScrfI digests wild-type DNA to yield 162-bp and 30-bp fragments (latter not shown). The intron C447-3G mutation abolishes the ScrfI site.
Panels B and D, C p control, N p patient N, U p undigested PCR product.
complexes of COX were present in samples overex-
pressing COX15. The in-gel activity assay showed res-
toration of COX activity in rescued fibroblasts (fig. 3B).
Mutation Detection in the COX15 Gene
Direct sequencing of a 1,155-bp RT-PCR cDNA frag-
ment of COX15 (variant 1) from patient N fibroblasts
showed a single transition mutation (C700T) compared
with the published sequence. This mutation, which ap-
peared homozygous in the cDNA, occurs in exon 5 of
the gene (fig. 4A) and corresponds to an Arg217Trp
(R217W) amino acid substitution. The presence of the
mutation was confirmed by restriction endonuclease di-
gest (StyI) of both the 1,155-nucleotide cDNA product
and a PCR-amplified exon 5 product from genomic
DNA. In contrast to the results obtained by cDNA se-
quencing, analysis of genomic DNA showed that the
C700T change was heterozygous (fig. 4B), suggesting
that the other disease allele might be a nonsense mu-
tation. The C700T substitution was not identified in 50
control individuals tested using the restriction endonu-
clease digest.
To identify the other disease allele, we amplified and
sequenced all eight common exons from COX15 and
both variants of exon 9, including the intron/exon bound-
aries, in patient N. This analysis identified a heterozygous
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Table 3
Relative Levels of Heme A and Heme O in Patient Heart
and Fibroblasts
RELATIVE LEVEL OF
Sample Heme A/B Heme O/B Heme A/O
Heart:
Control .221  .084 0 …
Patient N .014 .014 1.066
Fibroblasts:
Control .064 0 …
Control  COX15 .139 0 …
Patient N .030 0 …
Patient N  COX15 .090 0 …
NOTE.—Mitochondrial hemes were extracted and analyzed, as de-
scribed in the “Material and Methods” section. The values reported
in the table are calculated from integrals of hemes A, B, and O. The
value in control heart is an average of eight independent measure-
ments, the values in patient heart are result of two independent
measurements.
intron 3 splice-acceptor site transversionmutation (C447-
3G) at the conserved –3 position (fig. 4C). This hetero-
zygous CrG mutation preceding the conserved AG ac-
ceptor site in intron 3 was confirmed using a ScrfI
restriction endonuclease digest (fig. 4D). Patient N was
also found to be homozygous for an SNP, T1171C
(F374L), in variant 2 of exon 9 (dbSNP [rs2231687]).
RT-PCR amplification of a segment of COX15 cDNA
encompassing exons 3–5 was performed on fibroblast
total RNA from patient N to test whether the C447-3G
mutation produced an abnormally spliced cDNA prod-
uct. This analysis identified two bands corresponding to
the expected product sizes, with and without the inclu-
sion of exon 4 (data not shown). A single PCR product,
whose size corresponded to the correctly spliced cDNA,
was observed in control individuals. Sequencing of the
smaller band from the patient showed the expected se-
quence with a clean deletion of exon 4. This deletion
removes a 187-bp fragment of mRNA and, thus, predicts
a frameshift mutation, resulting in a protein product
truncated because of a premature stop codon (fig. 5).
The quantity of the PCR product corresponding to the
smaller cDNA was greatly reduced compared with the
correctly spliced cDNA, presumably the result of the
nonsense-mediated mRNA decay pathway.
Sequencing of COX15 in five additional patients with
hypertrophic cardiomyopathy and COX deficiency did
not reveal any further mutations in these cases.
Role of COX15 in the Biosynthesis of Heme A
Yeast Cox15p is involved in the biosynthesis of heme
A, the modified prosthetic heme group present in the
COX holoenzyme complex (Barros et al. 2001, 2002).
The initial step in this pathway, the hydroxylation of
hemeO, is thought to be catalyzed by a three-component
mono-oxygenase consisting of Cox15p, ferredoxin, and
ferredoxin reductase. Yeast cox15 mutants have no de-
tectable heme A and have low levels of heme O (Barros
and Tzagoloff 2002). To investigate the effect of the
COX15 mutations in patient N on heme A levels, total
heme was isolated from patient and control heart and
fibroblast mitochondria and was analyzed by HPLC. Pa-
tient N heart mitochondria contained markedly reduced
levels of heme A and increased levels of heme O (fig.
6A). To quantify the extent of these changes, the levels
of heme A were normalized to heme B, the amount of
which was a relatively constant fraction of mitochon-
drial protein in the control and patient samples (table
3). The heme A content was reduced to 6% of control,
which corresponds well with the magnitude of the de-
crease in COX activity and the cytochrome aa3 levels in
heart tissue from the patient. Heme O was undetectable
in control samples but accumulated to levels similar to
that of heme A in patient heart, consistent with a defect
in the heme A biosynthetic pathway.
Low heme A was also detected in patient fibroblasts;
however, no heme O peak could be detected (table 3;
fig. 6B). Overexpression ofCOX15 in patient fibroblasts
increased the heme A levels threefold, raising the nor-
malized heme A levels to 65% of that in control fibro-
blast lines also overexpressing COX15. The magnitude
of this increase agrees well with the increase in COX
activity in the complemented patient fibroblast line.
Overexpression of COX15 in control fibroblasts in-
creased the heme A content twofold (table 3). The COX
content (fig. 3) and COX activity (table 2) in these con-
trol lines were also slightly increased, although the in-
crease in activity was not statistically significant (P 1
). Thus, the increase in heme A synthesis in patient.9
fibroblasts overexpressing COX15 rescues the activity
and assembly of the COX complex.
Discussion
This study establishes mutations in COX15 as an ad-
ditional cause of isolated COX deficiency associated
with fatal infantile hypertrophic cardiomyopathy. This
is the fifth COX assembly factor that has been associated
with autosomal recessive COX deficiency. Our results
also provide strong evidence that COX15 plays an es-
sential role in mitochondrial heme modification in hu-
man beings, as it does in yeast.
To identify the underlying molecular defect in auto-
somal recessive COX deficiencies in this and similar
cases, we have taken a functional complementation ap-
proach in which we have used a panel of retroviral
expression vectors to overexpress human COX assem-
bly genes, identified by homology to their yeast counter-
parts. COX activity in fibroblasts from patient N was
specifically and reproducibly restored to ∼60% of con-
trol levels by transduction with a COX15.1 cDNA con-
Figure 5 Genomic structure of COX15, predicted protein sequences of human COX15 variants, and location of patient mutations. A,
Genomic structure of COX15. The solid vertical bars represent the 9 exons, and the open boxes represent the 5′ and 3′ untranslated regions
of the gene. Horizontal lines represent introns. Two-splice variants of the human gene have been described (COX15.1 and COX15.2) that
differ in the 3′ end of the mRNA. The splice-site mutation in patient N results in skipping of exon 4 in the mature transcript. The missense
mutation occurs in exon 5 and is indicated with an asterisk. B, The predicted protein sequence of the human COX15.1 and COX15.2 variants
are shown in single amino acid code. The size of predicted proteins is shown in parentheses. The C-terminal region in which the COX15.2
species diverges from COX15.1 is indicated in bold italics. The missense mutation (R217W) and the predicted C-terminal end of the truncated
protein resulting from the splice-site allele in patient N are shown in bold. Exon 4, which is deleted by the splice-site mutation, is boxed. The
predicted (MITOPROT II) canonical mitochondrial targeting sequence is underlined, and the predicted transmembrane domains (ENSEMBL)
are indicated with wavy lines. C, The short evolutionarily conserved sequence containing the missense mutation is shown.
Figure 6 Analysis of mitochondrial hemes in heart tissue and fibroblasts. Total hemes were extracted from isolated mitochondria with
acidic acetone and separated by reverse phase HPLC. The heme B, heme A, and heme O peaks were identified from the elution times of known
standards. The areas under the heme B, heme A, and heme O peaks were quantified and are reported in arbitrary units (in parentheses).
Chromatograms are shown from heart mitochondria (A) and from fibroblast mitochondria (B) isolated from cells with andwithoutoverexpression
of COX15. The insert shows that no heme O was detectable in the extract from patient fibroblasts.
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struct. No significant changes in COX activity were ob-
served in the patient cells with any of the other COX
assembly gene constructs. Overexpression of COX15
did not significantly alter the COX activity in 12 fibro-
blast lines from patients with isolated COX deficiency
resulting from SURF1, COX10, or SCO2 mutations or
other, unidentified gene defects. These data indicated
that there is no functional overlap among the COX
assembly factors and strongly suggested that mutations
in COX15 were responsible for the COX deficiency in
patient N.
Sequence analysis of COX15 revealed two hetero-
zygous mutations at evolutionarily conserved positions
common to the two-splice variants of COX15. The
C700T missense mutation results in the substitution of
tryptophan for a highly conserved arginine. TheR217W
substitution occurs in the region of a 21–amino acid
segment between transmembrane domains three and
four (fig. 5) in a string of eight highly conserved residues,
PRVSQYRL. The arginine residue is present in all se-
quenced mammalian and some yeast species. The splice
acceptor site mutation, which occurs in the3 position
of intron 3, is predicted to abolish this site and produce
a misspliced cDNA with a premature stop codon (fig.
5). Aberrant splicing of the mRNA produced by this
allele was demonstrated by the identification of a short
transcript with a clean deletion of exon 4. The relative
rarity of this transcript (compared with that transcribed
from the other allele) and the highly truncated protein
predicted by the premature stop codon suggest that the
allele is functionally null.
The COX15 gene was originally identified by func-
tional complementation studies of respiratory deficient
yeast with an isolated COX assembly defect (Glerum
et al. 1997). A human COX15 homologue was sub-
sequently identified by homology to the yeast gene and
mapped to chromosome 10 (Petruzzella et al. 1998). In
both yeast and human beings, the COX15 protein prod-
uct localizes to the inner mitochondrial membrane and
has several predicted transmembrane domains (fig. 5)
(Glerum et al. 1997; Petruzzella et al. 1998). In yeast,
Cox15p functions in the biosynthesis of heme A, the
prosthetic group of cytochrome a and a3. The synthesis
of heme A begins with farnesylation of the vinyl group
at carbon C-2 of protoheme (heme B) to form heme O,
a reaction catalyzed by Cox10p (heme A:farnesyltrans-
ferase) (Tzagoloff et al. 1993; Glerum and Tzagoloff
1994). Cox15p mediates hydroxylation of the methyl
group at the C-8 position of the heme O molecule, a
reaction thought to occur in concert with two other
inner mitochondrial membrane proteins, ferredoxin
(Yah1p) and ferredoxin reductase (Arh1p), which to-
gether function as a heme mono-oxygenase (Barros et
al. 2001, 2002; Barros and Tzagoloff 2002). The en-
zyme responsible for converting the C-8 hydroxymethyl
to a formyl group has not yet been identified. The heme
profiles of different COX assembly mutants in yeast
suggest positive regulation of heme B farnesylation by
the hydroxylated intermediate formed at the subsequent
step or by Cox15p itself (Barros and Tzagoloff 2002).
A deletion of COX15 in yeast results in undetectable
levels of heme A but detectable levels of heme O (Barros
et al. 2001). This pattern contrasts with that seen in
a COX10 deletion, where heme O and heme A are
undetectable, consistent with a role of Cox10p in the
synthesis of heme O from protoheme (Tzagoloff et
al. 1993).
Patient N had severely decreased levels of mitochon-
drial heme A and increased heme O levels in her heart
as compared with control levels. Fibroblasts from the
patient also showed a marked reduction in heme A but
no evidence for an accumulation of heme O. Cyto-
chrome aa3 was absent in patient heart mitochondria
when analyzed by difference spectroscopy. These find-
ings are similar to the pattern observed in yeast COX15
deletion mutants, suggesting a similar functional role
for COX15 in mammalian mitochondria and a similar
pathogenesis for the COX deficiency. The function of
the two-splice variants of COX15 remains unknown.
The pattern of expression of the mRNAs coding for the
two isoforms in different tissues is similar to that seen
with other COX assembly genes, apparently reflecting
tissue-specific mitochondrial content, although the
steady-state concentration of COX15.2 is much less
than that of COX15.1 (Petruzzella et al. 1998).
COX15.2 differs from COX15.1 in both the region
coding for the C-terminal end of the protein and the 3′-
UTR (fig. 5). In our complementation experiments, we
used only COX15.1 and never obtained complete rescue
of COX activity in patient fibroblasts. Similar experi-
ments in fibroblast cell lines from patients with SURF1,
SCO2, SCO1, or COX10 mutations, using the appro-
priate expression vectors, have resulted in virtually com-
plete rescue of COX activity in most cases, so it is un-
likely that incomplete rescue is a trivial artifact of the
expression system we used. One possibility is that both
isoforms of COX15 are necessary for optimal function
of the enzyme, and we are currently testing this
hypothesis.
Patient N manifested with a severe COX deficiency in
cardiac muscle and a milder COX deficiency in skeletal
muscle, liver, kidney, and fibroblasts. The decrease of
COX activity in patient fibroblasts (∼70%) was accom-
panied by a similar decrease (∼50%) in the amount of
fully assembled COX complex, suggesting that the resid-
ual holoenzyme complex in fibroblasts is fully active and
that the COX deficiency in this case results from an in-
ability to assemble sufficient enzyme because of reduced
availability of heme A. Studies on a human leukemia cell
line have identified three intermediates (subcomplexes)
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in the assembly of the holoenzyme complex that have
been called S1–S3. (Nijtmans et al. 1998). The first steps
in the assembly process are thought to involve the ad-
dition of heme a, heme a3, copper at the CuB site, and
COX IV to S1 (the COX I subunit) to form the S2 sub-
complex (Nijtmans et al. 1998). The formation of S3
involves addition of copper to the CuA site and most of
the other nuclear-encoded subunits, except VIa and VIIa
or -b, which are added in the final stage of assembly to
form S4, the fully assembled enzyme. The fact that no
subcomplexes could be detected in mitochondria from
patient heart tissue by BN-PAGE analysis suggests the
decrease in the COX complex content is caused by a
block in assembly at an early stage, most likely at S1.
This conclusion is consistent with the above model in
which heme A is required for the formation of the S2
subcomplex, and is further supported by the observation
that the S2 subcomplex accumulates in patients with
SURF1 mutations (Coenen et al. 1999; Tiranti et al.
1999), showing that this species is not an inherently un-
stable intermediate in the assembly process.
The molecular basis for the tissue-specific patterns of
COX deficiency, and the resultant tissue-specific clinical
phenotypes, in patients with mutations in COX assem-
bly genes remains elusive. SCO2 is the only other known
gene defect associated with hypertrophic cardiomyopa-
thy and isolated COX deficiency (Papadopoulou et al.
1999; Jaksch et al. 2000, 2001). These patients have a
severe reduction in COX activity in heart that is similar
to that observed in the patient withCOX15we describe
here. However, the deficiency in patients with SCO2
also occurs in skeletal muscle, whereas the COX defect
in the muscle of patient N was moderate. Most strik-
ingly, patients with mutations in COX10, which pre-
vents the synthesis of heme A by blocking heme O syn-
thesis, rather than heme A synthesis itself, have a
completely different phenotype—tubulopathy and leu-
kodystrophy (Valnot et al. 2000b). However, mutations
in COX10 and COX15 have so far only been identified
in single affected families, and it is possible that a range
of clinical phenotypes will eventually be associated with
mutations in these genes.
As far as is known, the COX assembly factors are
housekeeping genes that are transcribed in proportion
to other mitochondrial genes. There is no evidence yet
for tissue-specific expression of any of the known ac-
cessory proteins. As reagents are developed to analyze
the proteins themselves, it will be possible to look at
post-transcriptional or post-translational effects that
may turn up tissue-specific patterns of expression. An-
other possibility is that the tissue specificity reflects dif-
ferences in the regulation of the pathways of COX as-
sembly in different tissues. Consistent with this notion
is the observation that, although heme O levels in-
creased in heart mitochondria of patient N, this species
was undetectable in fibroblast mitochondria, raising the
possibility of tissue-specific regulation of the heme-bio-
synthetic pathway.
In conclusion, this study establishes mutations in
COX15 as an additional cause, along with SCO2, of
fatal infantile, hypertrophic cardiomyopathy associated
with COX deficiency. Sequencing of both of these genes
in five other cases with a similar clinical and biochemical
phenotype failed to identify pathogenic mutations, in-
dicating that there is additional genetic heterogeneity in
this group of disorders.
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